Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942665 | 0.98 | TSHR (0.49) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 | |
| SCHEMBL16071577 | 0.92 | TSHR (0.54) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 | |
| SCHEMBL22652957 | 0.89 | TSHR (0.46) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 | |
| SCHEMBL7598384 | 0.88 | TSHR (0.49) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 | |
| SCHEMBL14445068 | 0.88 | TSHR (0.52) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 | |
| SCHEMBL23841232 | 0.87 | TSHR (0.47) | TSHRSMN1; SMN2EPHX2RECQLKDM4E | |
| SCHEMBL21237600 | 0.87 | TSHR (0.47) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 | |
| SCHEMBL22882753 | 0.87 | TSHR (0.61) | TSHRSMN1; SMN2EPHX2RECQLKDM4E | |
| SCHEMBL23267578 | 0.87 | TSHR (0.47) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 | |
| SCHEMBL19556855 | 0.87 | MEN1 (0.52) | TSHRSMN1; SMN2CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2024-07-04 | — | — | US | disclosed |
| WO-2024028282-A1 | SITE-SPECIFIC MODIFICATION BY A BBB-SHUTTLE OF ANTIBODY-BASED ENTITIES FOR CROSSING THE BLOOD-BRAIN BARRIER | GATE2BRAIN, S.L. (ES) | 2024-02-08 | — | — | WO | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2023-08-15 | — | — | US | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022002022-A1 | RADIONUCLIDE LABEL AND USE THEREOF | 北京拓界生物医药科技有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-10988523-B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2021-04-27 | — | — | US | disclosed |
| US-10961295-B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2021-03-30 | — | — | US | disclosed |
| WO-2019149781-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2019-08-08 | — | — | WO | disclosed |
| US-20190233494-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | IRBM S.P.A. (IT) | 2019-08-01 | — | — | US | disclosed |
| US-20190233493-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2019-08-01 | — | — | US | disclosed |
| EP-3016975-B1 | DERIVATIVES OF GLP-1 LIKE PEPTIDES, AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-01-16 | — | — | EP | disclosed |
| US-20160289283-A1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NOVO NORDISK (DK) | 2016-10-06 | — | — | US | disclosed |
| US-8034900-B2 | Water-soluble thioester and selenoester compounds and methods for making and using the same | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100261637-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-10-14 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289283-A1 | SELECTIVE PYY COMPOUNDS AND USES THEREOF | NPY1R, NPY5R, NPY2R | TSHR 417/4885SMN1; SMN2 4522/4885CASP1 3781/4885 |
| US-20190233494-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP3 | TSHR 61/4885SMN1; SMN2 2931/4885CASP1 2406/4885 |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | GLP1R, GIPR, IAPP | TSHR 186/4885SMN1; SMN2 2696/4885CASP1 178/4885 |
| US-20190233493-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, SCTR, RXFP2 | TSHR 59/4885SMN1; SMN2 3012/4885CASP1 3254/4885 |
| US-10988523-B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | RXFP1, RXFP2, SCTR | TSHR 52/4885SMN1; SMN2 3035/4885CASP1 3037/4885 |
| US-20240218042-A1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | RXFP1, RXFP2, RXFP4 | TSHR 581/4885SMN1; SMN2 2683/4885CASP1 2821/4885 |
| US-20100261637-A1 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE | GLP1R, IAPP, GIPR | TSHR 586/4885SMN1; SMN2 3075/4885CASP1 1176/4885 |
| US-11725036-B2 | Modified lipidated relaxin B chain peptides and their therapeutic use | SCTR, RXFP1, RXFP3 | TSHR 40/4885SMN1; SMN2 2588/4885CASP1 3169/4885 |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | TSHR 323/4885SMN1; SMN2 1930/4885CASP1 3727/4885 |
| US-10961295-B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | RXFP1, SCTR, RXFP2 | TSHR 37/4885SMN1; SMN2 2321/4885CASP1 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.